AU2018229079A1 - Granzyme B inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling - Google Patents

Granzyme B inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling Download PDF

Info

Publication number
AU2018229079A1
AU2018229079A1 AU2018229079A AU2018229079A AU2018229079A1 AU 2018229079 A1 AU2018229079 A1 AU 2018229079A1 AU 2018229079 A AU2018229079 A AU 2018229079A AU 2018229079 A AU2018229079 A AU 2018229079A AU 2018229079 A1 AU2018229079 A1 AU 2018229079A1
Authority
AU
Australia
Prior art keywords
administration
gzmb
skin
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018229079A
Other languages
English (en)
Inventor
David James Granville
Valerio RUSSO
Yue Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2018229079A1 publication Critical patent/AU2018229079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018229079A 2017-02-28 2018-02-28 Granzyme B inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling Abandoned AU2018229079A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465055P 2017-02-28 2017-02-28
US62/465,055 2017-02-28
US201762611188P 2017-12-28 2017-12-28
US62/611,188 2017-12-28
PCT/CA2018/050230 WO2018157244A1 (en) 2017-02-28 2018-02-28 Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling

Publications (1)

Publication Number Publication Date
AU2018229079A1 true AU2018229079A1 (en) 2019-10-10

Family

ID=63369653

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018229079A Abandoned AU2018229079A1 (en) 2017-02-28 2018-02-28 Granzyme B inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling

Country Status (8)

Country Link
US (2) US20200016125A1 (enExample)
EP (1) EP3589304A4 (enExample)
JP (2) JP2020510655A (enExample)
KR (1) KR20190140907A (enExample)
AU (1) AU2018229079A1 (enExample)
IL (1) IL268860A (enExample)
MX (1) MX2019010230A (enExample)
WO (1) WO2018157244A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021050978A1 (en) * 2019-09-11 2021-03-18 University Of Cincinnati Treatment of skin blistering diseases using antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015296675B2 (en) * 2014-08-01 2020-04-30 Vida Therapeutics, Inc. Cyclic urea compounds as Granzyme B inhibitors
US20190038602A1 (en) * 2016-02-03 2019-02-07 Vida Therapeutics, Inc. Granzyme b inhibitor formulations and methods for the treatment of burns

Also Published As

Publication number Publication date
EP3589304A4 (en) 2020-11-25
KR20190140907A (ko) 2019-12-20
US20200016125A1 (en) 2020-01-16
JP2020510655A (ja) 2020-04-09
WO2018157244A1 (en) 2018-09-07
MX2019010230A (es) 2019-11-21
JP2023062141A (ja) 2023-05-02
EP3589304A1 (en) 2020-01-08
IL268860A (en) 2019-10-31
US20230233526A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
ES2924479T3 (es) Composiciones para rejuvenecer las células madre del músculo esquelético
KR20170003527A (ko) 경구 투여용 펜토산 폴리설페이트 염의 조성물
TW201927782A (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
TWI620738B (zh) 聚蛋白多糖酶抑制劑
KR20180093930A (ko) 통각과민증을 치료하는 방법
Naidu et al. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines
US10426815B2 (en) Prevention and treatment of itch with an MRGPR antagonist
KR20170084067A (ko) C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
AU2010243314B2 (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
Lu et al. Therapeutic targeting of mechanical stretch-induced FAK/ERK signaling by fisetin in hypertrophic scars
US20230233526A1 (en) Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling
EP3046560B1 (en) Stem cell modulation ii
JP2021516225A (ja) イミダゾジアゼピンジオン及びその使用方法
WO2012113785A1 (en) Methods for treating and diagnosing disease
JP2021531308A (ja) 腎障害の処置で使用するための化合物
JP6937738B2 (ja) 特定の泌尿器系障害の治療における使用のためのｉｌ−８阻害剤
WO2019050429A1 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
EP3156064B1 (en) Application of yb-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease
US20220024981A1 (en) Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2014139014A1 (en) Methods and compositions for the inhibition of vascular endothelial growth factor activity and vascular permeability
Kan et al. Inhibition of HDAC6 with CAY10603 alleviates acute and chronic kidney injury by suppressing the ATF6 branch of UPR
JP2025511786A (ja) 筋線維症の治療
WO2013090991A1 (en) Tgf-beta therapy
Bhattacharyya Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application